Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Wiskott-Aldrich Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Methotrexate (this asset) | Roswell Park Cancer Institute | P2 | B · 63 |
| Melphalan | Washington University School of Medicine | P2 | BB |
| Tacrolimus | Roswell Park Cancer Institute | P2 | BB |
| Fludarabine | Roswell Park Cancer Institute | P2 | BB |
| Thiotepa | University of Florida | P2 | BB |
| Alemtuzumab | Washington University School of Medicine | P2 | B |
| Human Immunoglobulins | Grifols Therapeutics LLC | P3 | B |
| Cyclophosphamide | Roswell Park Cancer Institute | P2 | CCC |
| Cyclosporin A | Children's Hospital Los Angeles | P1/2 | CCC |
+8 more in the Wiskott-Aldrich Syndrome cohort
Other indications for Methotrexate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Acute Promyelocytic Leukemia | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Methotrexate in Wiskott-Aldrich Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/methotrexate-wiskott-aldrich-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →